维思通及卓菲治疗精神分裂症临床对照研究.docVIP

维思通及卓菲治疗精神分裂症临床对照研究[摘要] 目的:通过分析合资维思通与国产卓菲治疗精神分裂症的临床效果,根据家境和个体情况选取药物。方法:将70例精神分裂症患者随机分为两组,经8周治疗,以CCMD-3精神分裂症的诊断标准、PANSS评定疗效,TESS评定副作用。结果:两组治疗后PANSS评分与治疗前比较,均有显著性差异;治疗后随治疗时间延长而下降,副作用少,说明两药治疗精神分裂症效果显著。结论:维思通疗效比卓菲好,起效快;不良反应卓菲比维思通高;但两者的疗效和副作用比较均无显著性差异,而价格有差别。临床可根据患者经济状况和个体差异来选择使用。 [关键词] 精神分裂症;维思通;卓菲;疗效 [中图分类号] R749.3[文献标识码]A [文章编号]1673-7210(2009)07(c)-062-02 Clinical control study of Weisitong and Zhuofei on schizophrenia LUO Laixing (The Second People’s Hospital of Huizhou, Huizhou516001, China) [Abstract] Objective: To discuss the clinical effect of joint-stock Risperidone(Weisitong) and domestic Risperidone(Zhuofei) on schizophrenia. The choosing of the two medicaments was based on the family financial situation and individual difference. Methods: 70 patients with schizophrenia were randomly divided into two groups, after 8 weeks of treatment, all the patients were selected in accordance with the CCMD-3 diagnosis standard. The clinical effect of patients were measured by the PANSS and the side effects were evaluated with the TESS. Results: There was significant differences on PANSS between pre- treatment and post-treatment. The score declines and the side effect decreased with the prolonging of time. This showed that the two medicaments had evident clinic efficacy on schizophrenia. Conclusion: Joint-stock Risperidone show better effect and faster effect than domestic Risperidone, but the side effects by contraries. There is not significant differences on curative effect and side effect, but the price show difference. So we can choose anyone according to the economy status and individual difference. [Key words] Schizophrenia; Weisitong; Zhuofei; Curative effect 合资维思通和国产卓菲均属苯丙异唑衍生物,具有较强的五羟色胺2A(5-HT2A)和多巴胺2(D2)受体阻断作用,能有效改善精神病的阳性和阴性症状以及认知损害,锥体外系副作用发生率低[1]。大量临床实践证实其是一种疗效较高、安全性较好的新型抗精神分裂症药。因两药价格上有差异,为验证其疗效及安全性进行临床对照分析,现报道如下: 1 资料与方法 1.1 一般资料 观察对象为我院2008住院患者。入组标准:符合CCMD-3精神分裂症的诊断标准[2]。年龄17～55岁,病程2个月～25年。阳性与阴性症状量表(PANSS)总分≥60分,排除严重躯体疾病及其他严重肝肾疾